Beyond BRAF V600: emerging MAPK-targeted therapeutic strategies

Review Article | Biomarkers Sciences Introduction The therapeutic landscape of advanced melanoma has undergone a profound transformation over the past 15 years. The introduction of immune checkpoint inhibitors ( 1 ) and selective BRAF/MEK inhibitor combinations ( 2 - 4 ) has converted a previously fatal disease into one in which long-term survival is now achievable for a substantial proportion of patients.

Nevertheless, targeted drugs have been developed only for the approximately 40–50% of patients whose tumors harbor activating BRAF V600 mutations (class I mutations) ( 5 ). By contrast, patients with melanoma driven by alternative mitogen-activated protein kinase (MAPK) pathway alterations ( 6 ), particularly activating NRAS mutations or NF1 loss, continue to face limited therapeutic options and poorer clinical outcomes.

NRAS mutations are detected in approximately 20–30% of melanomas and represent the second most common oncogenic driver after BRAF ( 6 ) . Unlike BRAF V600-mutant tumors, which signal predominantly through constitutively active BRAF monomers, NRAS -mutant melanomas depend on a far more complex signaling network involving RAF dimerization, preferential CRAF activation, and multiple adaptive feedback mechanisms ( 7 - 9 ).

These biological differences have largely explained the disappointing clinical activity observed with conventional BRAF inhibitors (BRAFi) and the modest benefit achieved with MEK inhibition alone. The only randomized phase III trial specifically developed for NRAS -mutant melanoma, NEMO, demonstrated that the MEK inhibitor binimetinib produced only a modest improvement in progression-free survival (PFS) compared with dacarbazine, without a meaningful overall survival (OS) advantage ( 10 ).

Consequently, immune checkpoint blockade remains the standard systemic treatment for these patients, whereas no targeted therapy has received regulatory approval despite more than two decades of intensive research. Recent advances in structural biology, medicinal chemistry, and systems biology have substantially reshaped our understanding of MAPK signaling.

Rather than considering RAF proteins as isolated kinases, current models recognize highly dynamic signaling complexes involving RAF homo- and heterodimers, scaffold proteins, RAS nanoclusters, and multiple feedback regulators. These discoveries have directly inspired the development of several entirely new therapeutic classes designed not simply to inhibit kinase activity but to manipulate protein interactions, stabilize inactive signaling complexes, induce selective protein degradation, or prevent adaptive pathway reactivation.

Among these emerging agents, type II pan-RAF inhibitors have generated particular interest because of their ability to inhibit multiple RAF isoforms, including CRAF-dependent signaling characteristic of NRAS -mutant melanoma ( 11 - 13 ). Clinical studies evaluating belvarafenib ( 12 , 14 ), naporafenib ( 11 ), exarafenib ( 11 , 13 ), and other compounds have demonstrated antitumor activity.

Simultaneously, several innovative approaches, including RAF-MEK molecular glues, RAF-MEK clamps, paradox breakers, proteolysis-targeting chimeras (PROTACs), and tri-complex RAS inhibitors, are expanding the therapeutic arsenal against MAPK-driven cancers. Importantly, these agents are not being developed exclusively for NRAS -mutant melanoma.

Their biological rationale extends across multiple malignancies characterized by class II or class III BRAF mutations, NF1 loss, RAF fusions, RAS-dependent tumors, and acquired resistance to first-generation MAPK inhibitors. The renaissance of RAS-targeted drug development has further accelerated this field.

For decades, RAS proteins were considered “undruggable”, largely because of their high affinity for GTP and the absence of suitable drug-binding pockets. This paradigm changed dramatically with the clinical development of KRAS G12C inhibitors, which established direct RAS inhibition as a feasible therapeutic strategy and transformed the treatment landscape of several malignancies, particularly non-small cell lung cancer ( 15 - 17 ).

These successes have stimulated the rapid development of next-generation pan-RAS inhibitors and RAS tri-complex inhibitors capable of targeting a broader spectrum of RAS alterations ( 18 , 19 ). Although these agents are not yet in advanced clinical development for melanoma, their mechanisms of action make them particularly attractive for tumors driven by NRAS mutations or NF1 loss, both of which remain critically dependent on upstream RAS signaling ( 20 ).

Consequently, advances in RAS-directed therapeutics may ultimately expand treatment opportunities beyond KRAS -mutant cancers and reshape the management of MAPK-driven melanoma. In parallel, increasing recognition of adaptive resistance pathways involving focal adhesion kinase (FAK) ( 21 , 22 ), YAP signaling ( 23 ), receptor tyrosine kinase (RTK) reactivation, SOS1 -mediated RAS activation, and metabolic vulnerabilities such as MTAP deletion is fostering a new generation of rational combination strategies ( 24 ).

Rather than relying on single-agent kinase inhibition, future treatment paradigms will probably integrate multiple complementary approaches capable of suppressing both primary oncogenic signaling and adaptive escape mechanisms. This review discusses the biological basis underlying these emerging therapeutic strategies, critically evaluates current preclinical and clinical evidence, and explores how next-generation MAPK inhibitors may redefine precision medicine for NRAS -mutant melanoma and other MAPK-driven malignancies.

MAPK signaling biology and functional classification of BRAF mutations The MAPK cascade is one of the most highly conserved intracellular signaling networks regulating cellular proliferation, differentiation, survival, metabolism, and apoptosis. In melanoma, constitutive activation of this pathway represents the dominant oncogenic event and is driven by genetic alterations affecting components upstream or within the RAS-RAF-MEK-ERK signaling axis ( 7 , 25 ).

Although therapeutic advances have historically focused on BRAF V600 mutations, increasing knowledge of MAPK biology has revealed that signaling dynamics differ substantially according to the molecular context, providing the biological rationale for the development of a new generation of inhibitors.

Activation of the pathway begins with stimulation of RTKs, leading to recruitment of adaptor proteins and activation of the guanine nucleotide exchange factor SOS1 , which catalyzes the exchange of GDP for GTP on RAS proteins. In their GTP-bound conformation, RAS proteins undergo conformational changes within the switch I and switch II regions that enable interaction with multiple downstream effectors, among which the RAF serine/threonine kinases represent the principal mediators of MAPK signaling.

The RAF family comprises ARAF , BRAF , and CRAF ( RAF1 ), each displaying distinct kinase activity, regulatory mechanisms, and tissue-specific functions. Following activation by RAS, RAF proteins phosphorylate MEK1/2, which subsequently activate ERK1/2, ultimately regulating hundreds of transcription factors and cellular processes involved in tumor progression ( 8 ).

Although this linear representation remains useful for conceptual purposes, MAPK signaling is now recognized as a highly dynamic network controlled by feedback loops, scaffold proteins, kinase dimerization, and spatial organization within membrane-associated nanoclusters. These regulatory mechanisms largely explain both the remarkable efficacy of first-generation BRAFi in selected patients and the rapid emergence of adaptive resistance observed in most MAPK-driven tumors ( 26 ).

One of the most important advances over the past decade has been the functional classification of BRAF alterations according to their biochemical properties rather than their genomic location. Instead of considering all BRAF mutations as a single biological entity, they are now classified into three functional groups based on kinase activity, dependence on RAS activation, and dimerization status ( 27 , 28 ).

Class I mutations, represented almost exclusively by the V600 substitutions, are characterized by high kinase activity and signal as constitutively active monomers independently of upstream RAS activation. This unique biological behavior explains the extraordinary clinical efficacy of selective ATP-competitive BRAFi such as vemurafenib, dabrafenib, and encorafenib, particularly when combined with MEK inhibitors ( 27 , 28 ).

In contrast, Class II mutations exhibit intermediate to high kinase activity but require constitutive homodimer formation for signaling. Although these tumors remain largely RAS-independent, their dimeric conformation markedly reduces sensitivity to first-generation BRAFi, which preferentially inhibit monomeric BRAF .

Representative alterations include K601E, L597Q, and several activating BRAF fusions, all of which represent important therapeutic challenges across multiple tumor types. The greatest therapeutic challenge is represented by Class III mutations, which possess impaired or absent intrinsic kinase activity yet remain strongly oncogenic by amplifying signaling through activated RAS and wild-type RAF proteins.

Rather than functioning as autonomous kinases, these mutants increase the formation of BRAF - CRAF heterodimers and rely on upstream RTK or RAS activation to sustain downstream ERK signaling. Consequently, tumors harboring Class III mutations frequently coexist with activating alterations in RAS , NF1 , or RTKs and demonstrate intrinsic resistance to conventional BRAF inhibition ( 27 ) ( Figure 1 ).

Figure 1 Functional classification of BRAF mutations and their therapeutic implications within the MAPK pathway. BRAF alterations are categorized into three functional classes according to their kinase activity, RAS dependence, dimerization status, and sensitivity to targeted therapy.

Class I mutations, typified by BRAF V600E and V600K, exhibit high kinase activity and signal as constitutively active, RAS-independent monomers, accounting for their sensitivity to selective BRAFi, particularly when combined with MEK inhibition. Class II alterations, including K601E, L597Q, and BRAF fusions, signal predominantly as constitutively active RAF dimers and are largely RAS independent.

Their dimeric configuration limits the activity of conventional monomer-selective BRAFi and provides a rationale for therapeutic strategies capable of targeting RAF dimers. Class III BRAF mutations have impaired or absent kinase activity and depend on upstream RAS activation, frequently in the context of RTK signaling, activating RAS alterations, or NF1 loss.

These variants promote signaling through BRAF-CRAF heterodimers and are intrinsically resistant to conventional selective BRAF inhibition. This figure was generated using NoteBookLM. BRAFi, BRAF inhibitor.

This functional classification extends beyond BRAF itself and has important implications for understanding NRAS -mutant melanoma. Unlike BRAF V600-driven tumors, which signal predominantly through activated BRAF monomers, NRAS -mutant melanomas rely heavily on CRAF -mediated signaling ( 29 ).

Early experimental studies demonstrated that genetic depletion of CRAF , but not BRAF , abolishes ERK activation and suppresses proliferation in NRAS -mutant melanoma cell lines, establishing CRAF as the principal downstream effector of oncogenic NRAS ( 29 ). These findings explain why selective inhibition of mutant BRAF has little therapeutic value in NRAS -mutant disease despite targeting the same signaling pathway ( Table 1 ).

Table 1 Characteristics of BRAF and NRAS mutant melanoma Characteristic BRAF V600 NRAS Frequency 40–50% 20–30% Predominant mutations V600E (~80%), V600K, V600R Q61R, Q61K, Q61L (>85%); less frequently G12 and G13 Dependence on RAF isoforms Predominantly BRAF monomers Predominantly CRAF and RAF dimers RAS dependency No Yes RAF dimer dependency Limited High Sensitivity to selective BRAFi Excellent Ineffective; paradoxical MAPK activation may occur Activity of MEK inhibitors Effective only in combination with BRAFi Limited clinical activity as monotherapy Approved targeted therapy BRAFi + MEKi combinations None Major mechanisms of resistance Secondary MAPK reactivation, BRAF amplification, splice variants, RTK activation RAF dimerization, CRAF dependence, RTK activation, PI3K signaling, FAK, YAP, SOS1 , ERK reactivation Most promising emerging therapies RAF degraders, paradox breakers, next-generation BRAFi Pan-RAF inhibitors, pan-RAS inhibitors, RAF-MEK molecular glues, RAF-MEK clamps Comparison of the biological features, signaling dependencies, currently available therapies, and emerging therapeutic opportunities in BRAF V600- and NRAS -mutant melanoma.

Unlike BRAF V600 tumors, which are largely driven by constitutively active BRAF monomers and respond to selective BRAF inhibition, NRAS -mutant melanomas exhibit marked dependence on CRAF -mediated signaling, RAF dimerization, and adaptive pathway rewiring. These biological differences provide the rationale for the development of next-generation MAPK- and RAS-targeted therapies.

BRAFi, BRAF inhibitor; MEKi, MEK inhibitor. Another fundamental concept that has reshaped MAPK-directed drug development is RAF dimerization. Physiologically, RAS activation promotes the formation of RAF homo- and heterodimers at the plasma membrane, enabling efficient MEK phosphorylation.

However, first-generation BRAFi were specifically designed to bind monomeric mutant BRAF and unintentionally promote dimerization of wild-type RAF proteins. In RAS-active cells, drug binding to one protomer induces transactivation of the partner kinase, resulting in paradoxical activation of ERK signaling.

Clinically, this phenomenon explains the development of cutaneous squamous-cell carcinomas, keratoacanthomas, and other hyperproliferative lesions observed during treatment with selective BRAFi, as well as their limited efficacy in tumors driven by RAF dimers ( 30 ). Recognition of the central role of RAF dimerization has fundamentally transformed therapeutic development.

Rather than designing increasingly potent inhibitors of mutant BRAF monomers, current strategies aim to inhibit both monomeric and dimeric RAF complexes, selectively target CRAF-dependent signaling, stabilize inactive RAF-MEK assemblies, or prevent adaptive dimer formation altogether.

These concepts have given rise to several novel therapeutic classes, including type II pan-RAF inhibitors, paradox breakers, RAF-MEK molecular glues, RAF-MEK clamp inhibitors, and RAF degraders, which seek to overcome the intrinsic limitations of first-generation BRAFi. Importantly, the increasing availability of direct RAS inhibitors further broadens this therapeutic landscape.

Next-generation pan-RAS tri-complex inhibitors have demonstrated preclinical activity across multiple RAS isoforms, including NRAS ( 31 ). These advances reinforce the concept that MAPK inhibition should no longer be viewed as a strategy restricted to mutant BRAF but rather as a continuum of therapeutic approaches targeting distinct nodes of an interconnected signaling network.

Understanding these biological principles is essential for interpreting the mechanisms of action, efficacy, and resistance of the next generation of MAPK-targeted therapies discussed in the following sections. NRAS -mutant melanoma Activating NRAS mutations represent the second most common oncogenic driver in cutaneous melanoma, occurring in approximately 15–25% of cases and defining a biologically distinct subgroup characterized by constitutive MAPK pathway activation, aggressive clinical behavior, and the absence of approved targeted therapies ( 32 ) ( Table 1 ).

More than four decades after the identification of NRAS as the first oncogene implicated in melanoma pathogenesis, therapeutic progress has remained remarkably limited, contrasting sharply with the success achieved in BRAF V600-mutant disease. Among the three RAS isoforms, NRAS is by far the predominant family member altered in melanoma, whereas KRAS and HRAS mutations occur only rarely.

The vast majority of NRAS alterations involve codon 61, with Q61R, Q61K and Q61L accounting for nearly 90% of mutant tumors, while substitutions affecting codons 12 and 13 are considerably less frequent ( 32 ). Functional studies have demonstrated that these mutations impair the intrinsic GTPase activity of NRAS , locking the protein in its active GTP-bound conformation and producing persistent downstream signaling through multiple effector pathways, including RAF-MEK-ERK, PI3K-AKT-mTOR, Ral-GDS, and phospholipase C pathways ( Table 1 ).

Although frequently considered as a single molecular entity, accumulating evidence suggests that different NRAS alleles exhibit distinct biological properties. Experimental models have demonstrated that codon 61 variants differ in their tumorigenic potential, signaling intensity, and metastatic behavior, with Q61R and Q61K generally producing more aggressive phenotypes than other substitutions ( 32 , 33 ).

These observations suggest that the biological heterogeneity of NRAS -mutant melanoma may eventually have therapeutic implications, particularly as increasingly selective RAS -directed inhibitors enter clinical development. This preferential dependence on CRAF fundamentally explains why selective BRAFi are ineffective in NRAS -mutant tumors and highlights RAF dimer biology as a critical therapeutic vulnerability ( Figure 2 ).

Oncogenic NRAS simultaneously activates several interconnected signaling networks, generating extensive crosstalk between MAPK, PI3K-AKT, RHO GTPases, YAP/TAZ signaling, FAK, and RTK pathways. In addition, multiple negative feedback mechanisms within the MAPK cascade are rapidly relieved following pharmacological inhibition, facilitating adaptive ERK reactivation and limiting the durability of targeted therapies.

These characteristics contribute to the intrinsic resilience of NRAS -driven tumors and largely explain the modest activity observed with single-agent MAPK inhibitors. Figure 2 MAPK pathway activation and RAF dimerization in NRAS -mutant melanoma. Oncogenic NRAS activation or loss of the RAS GTPase-activating protein NF1 promotes accumulation of GTP-bound RAS and sustained MAPK pathway signaling.

SOS1 -mediated nucleotide exchange further facilitates conversion of RAS-GDP to its active RAS-GTP state. Activated NRAS recruits RAF proteins to the plasma membrane, promoting RAF dimerization, including BRAF-CRAF heterodimer formation. RAF dimers subsequently activate MEK1/2 through phosphorylation, followed by ERK1/2 activation and nuclear translocation.

Nuclear ERK regulates transcriptional programs controlling cell proliferation, survival, and metabolism. The dependence of NRAS -mutant melanoma on RAF dimerization represents a major limitation of first-generation, monomer-selective RAF inhibitors and provides the mechanistic basis for emerging approaches targeting RAS activation, RAF dimers, RAF-MEK complexes, and downstream MAPK signaling.

This Figure was generated using NoteBookLM. GDP, guanosine diphosphate; GTP, guanosine triphosphate. Clinically, NRAS -mutant melanoma is associated with distinctive epidemiological and pathological features.

Patients are typically older than those with BRAF -mutant melanoma ( 34 ), and tumors are more frequently located on chronically sun-damaged skin, reflecting the ultraviolet mutational signature characteristic of this molecular subtype ( 35 ). Several retrospective series have associated NRAS mutations with thicker primary tumors, increased mitotic activity, higher rates of nodal involvement, and poorer overall prognosis, although the independent prognostic value of NRAS remains somewhat controversial after adjustment for clinicopathological variables ( 34 , 36 ).

Immune checkpoint blockade currently represents the preferred first-line treatment for advanced NRAS -mutant melanoma. Nevertheless, a substantial proportion of patients eventually develop progressive disease, emphasizing the urgent need for effective targeted approaches capable of complementing or enhancing immunotherapy.

To date, the only randomized phase III trial specifically conducted in NRAS -mutant melanoma remains the NEMO study, which compared the MEK inhibitor binimetinib with dacarbazine after immunotherapy or chemotherapy. Although binimetinib significantly improved PFS (2.8 vs. 1.5 months) and objective response rate (ORR), responses were infrequent, short-lived, and failed to translate into an OS benefit ( 10 ).

A higher response rate was observed with other MEK inhibitor, tunalemetinib ( 37 ), but with a short duration of response around six months, confirming that blockade of a single downstream kinase is insufficient to suppress the complex signaling network maintained by oncogenic NRAS .

Several factors probably account for the disappointing clinical performance of MEK inhibitors. First, MEK inhibition does not prevent upstream RAF activation or the formation of adaptive RAF dimers. Second, ERK signaling rapidly recovers through multiple feedback mechanisms involving RTKs, SHP2 , SOS1 , and alternative RAF complexes.

Third, NRAS simultaneously activates parallel survival pathways, including PI3K-AKT, which remain largely unaffected by MEK inhibition. Finally, genomic heterogeneity and co-occurring alterations involving NF1 , CDKN2A , PTEN , TERT , or chromatin remodeling genes further contribute to therapeutic resistance and biological diversity.

Importantly, therapeutic development in NRAS -mutant melanoma is now entering a new phase. Rather than attempting to inhibit a single downstream kinase, contemporary strategies aim to disrupt MAPK signaling at multiple complementary levels. These include inhibition of RAF dimers through type II pan-RAF inhibitors, stabilization of inactive RAF-MEK complexes using molecular glues or RAF-MEK clamps, degradation of mutant RAF proteins, inhibition of activated RAS through tri-complex inhibitors, and rational combinations targeting adaptive resistance pathways such as FAK, SOS1, ERK, or STAT3.

Collectively, these approaches reflect a fundamental shift from linear kinase inhibition toward systems-level modulation of MAPK signaling. Finally, the remarkable success of direct KRAS inhibition in non-small cell lung cancer ( 38 ) and, more recently, pancreatic ductal adenocarcinoma ( 18 ) has profoundly altered the therapeutic landscape of RAS-driven malignancies.

Although direct NRAS inhibition remains at an early stage of clinical development, RLY-8161, an NRAS-selective inhibitor designed to spare KRAS and HRAS , has entered a first-in-human Phase I trial in patients with advanced NRAS -mutant melanoma and other NRAS -mutant solid tumors (NCT07584226).

Emerging pan-RAS inhibitors may further extend RAS-directed therapeutic opportunities in melanoma. Together with next-generation RAF inhibitors, these agents have the potential to transform a disease that has long represented one of the greatest unmet needs in precision oncology. Evolution of RAF inhibition The remarkable success of selective BRAFi fundamentally changed the treatment paradigm of advanced melanoma and established MAPK inhibition as one of the greatest achievements of precision oncology.

However, the clinical limitations observed outside BRAF V600-mutant tumors rapidly demonstrated that inhibition of a single mutant kinase was insufficient to address the biological complexity of MAPK-driven cancers. Over the last decade, advances in structural biology have transformed our understanding of RAF signaling, leading to successive generations of inhibitors designed to overcome RAF dimerization, paradoxical pathway activation, adaptive resistance, and signaling heterogeneity.

Rather than representing incremental improvements, these compounds embody a conceptual evolution from selective inhibition of mutant BRAF monomers to comprehensive modulation of the RAF signaling network ( Figure 3 , Table 2 ). Figure 3 Emerging therapeutic strategies for next-generation MAPK pathway inhibition in advanced melanoma.

The canonical RTK-RAS-RAF-MEK-ERK signaling cascade provides multiple opportunities for therapeutic intervention beyond conventional BRAF and MEK inhibition. Upstream strategies include SOS1 inhibitors, which suppress nucleotide exchange and RAS activation, and RAS-targeting tri-complex inhibitors designed to prevent productive RAF engagement.

At the RAF level, emerging approaches include type II pan-RAF inhibitors that target monomeric and dimeric RAF complexes, paradox-breaking RAF inhibitors designed to avoid unintended MAPK activation, RAF degraders, and molecular glues that modulate RAF-containing signaling complexes.

RAF-MEK clamps provide an additional strategy by stabilizing inactive RAF-MEK complexes and limiting adaptive pathway reactivation, whereas ERK inhibitors enable terminal blockade of MAPK signaling. Parallel and compensatory pathways, including PI3K-AKT, FAK, YAP/TAZ, and alternative ARAF-KSR1 -containing complexes, may contribute to therapeutic resistance and provide opportunities for rational combination strategies.

This figure was generated using NoteBookLM. Table 2 MAPK pathway inhibitors Agent Drug class Mechanism of action Primary molecular targets Potential indication Key efficacy findings Exarafenib Type II pan-RAF inhibitor ATP-competitive inhibitor of RAF monomers and dimers ARAF, BRAF, CRAF NRAS -mutant melanoma, class II/III BRAF , RAF fusions Durable responses in class II BRAF alterations; encouraging activity in NRAS-mutant melanoma Belvarafenib Type II pan-RAF inhibitor ATP-competitive inhibitor of RAF monomers and dimers ARAF, BRAF, CRAF NRAS -mutant melanoma, non-V600 BRAF ORR ~55% with cobimetinib in NRAS-mutant melanoma Naporafenib Type II pan-RAF inhibitor ATP-competitive inhibitor of RAF monomers and dimers ARAF, BRAF, CRAF NRAS -mutant melanoma, class II BRAF ORR ~47% with trametinib Tovorafenib Type II RAF inhibitor ATP-competitive inhibitor of RAF monomers and dimers; CNS penetration BRAF , CRAF , RAF fusions Pediatric low-grade glioma, RAF fusion-positive tumors High activity in BRAF fusion-driven tumors NST-628 RAF-MEK molecular glue Stabilizes inactive RAF-MEK complexes and prevents MEK phosphorylation All RAF isoforms NRAS -, KRAS -, and BRAF -mutant tumors Deep and durable MAPK suppression in preclinical models Avutometinib RAF-MEK clamp Stabilizes inactive RAF-MEK complexes RAF-MEK complex KRAS -, NRAS -, NF1 -mutant tumors Synergistic activity with FAK inhibition Daraxonrasib Tri-complex RAS inhibitor Binds active RAS-GTP and recruits cyclophilin A to prevent RAF engagement KRAS, NRAS, HRAS NF1 RAS-driven tumors Promising in NSCLC and pancreatic cancer CFT1946 RAF degrader (PROTAC) Ubiquitin-degradation of mutant BRAF Mutant BRAF BRAF V600, BRAF amplification, splice variants Active against mechanisms of acquired resistance to BRAFi Plixorafenib (PLX8394) Paradox breaker Selective BRAF inhibition without paradoxical MAPK activation Mutant BRAF Non-V600 BRAF , BRAF fusions, BRAF V600 resistant Broad activity across non-V600 alterations and BRAF fusions SOS1 inhibitors (e.g., BI-3406 class) SOS1 inhibitor Blocks GDP-GTP exchange on RAS SOS1 NF1 -deficient and RAS-driven tumors Strong preclinical synergy with MEK inhibition ERK inhibitors ERK inhibitor Inhibits terminal MAPK signaling downstream of RAF and MEK ERK1/2 MAPK-reactivated tumors Potential strategy to overcome MAPK reactivation FAK inhibitors (defactinib) FAK inhibitor Blocks focal adhesion kinase-mediated adaptive resistance FAK BRAF ; NRAS Synergistic with avutometinib and MAPK inhibition Emerging therapeutic strategies targeting the MAPK pathway beyond conventional BRAF inhibition.

Unlike first-generation BRAF inhibitors, these agents have been specifically designed to overcome RAF dimerization, CRAF dependence, adaptive MAPK reactivation, or upstream RAS signaling. Together, they illustrate the rapid evolution of precision medicine for NRAS -mutant melanoma, non-V600 BRAF alterations, NF1 -deficient tumors, and other MAPK-driven malignancies.

CNS, central nervous system; FAK, focal adhesion kinase; NSCLC, non-small cell lung cancer; ORR, objective response rate; PROTAC, proteolysis-targeting chimera. First-generation BRAFi The development of vemurafenib, followed by dabrafenib and encorafenib, revolutionized the treatment of BRAF V600-mutant melanoma.

These ATP-competitive inhibitors selectively bind the active conformation of monomeric mutant BRAF , resulting in rapid suppression of ERK signaling and unprecedented response rates exceeding 60–70% when combined with MEK inhibitors. Their success validated oncogene addiction as a therapeutic principle and established combined BRAF/MEK inhibition as a standard of care ( 2 , 3 ).

Despite these achievements, first-generation BRAFi were designed against a very specific molecular context: constitutively active BRAF monomers. As discussed in Section ”MAPK signaling biology and functional classification of BRAF mutations”, first-generation BRAFi are largely restricted to Class I BRAF mutations and may induce paradoxical MAPK activation in RAS-active, RAF dimer-dependent contexts.

This mechanistic limitation explains their lack of efficacy in NRAS -mutant melanoma and provided a major rationale for the development of next-generation RAF inhibitors capable of targeting RAF dimers and multiple RAF isoforms. Type II pan-RAF inhibitors Recognition of the central role of RAF dimerization directly inspired the development of type II pan-RAF inhibitors.

Unlike first-generation BRAFi, these compounds recognize the inactive DFG-out conformation of RAF kinases and inhibit both monomeric and dimeric complexes while simultaneously targeting multiple RAF family members, including ARAF , BRAF , and CRAF . This broader mechanism of action is particularly attractive in NRAS mutant melanoma.

By suppressing signaling irrespective of the specific RAF isoform involved, pan-RAF inhibitors have the potential to overcome one of the principal mechanisms limiting conventional BRAF inhibition. Several compounds have entered clinical development over the past few years, including belvarafenib ( 14 , 39 , 40 ), naporafenib ( 11 , 41 ), exarafenib ( 13 ), and tovorafenib ( 42 , 43 ).

Although they share the common objective of inhibiting RAF dimers, important pharmacological differences distinguish these agents, particularly regarding kinase selectivity, off-target activity, central nervous system penetration, and combination strategies. Mechanistically, these differences include variations in RAF-family selectivity and off-target kinase inhibition, which may influence the extent of pathway suppression and the therapeutic window of individual compounds.

Belvarafenib Belvarafenib was among the first pan-RAF inhibitors to demonstrate encouraging clinical activity in NRAS -mutant melanoma. Combined with the MEK inhibitor cobimetinib, ORRs approaching 55% and median PFS exceeding seven months were reported ( 40 ), substantially improving upon historical results achieved with MEK inhibition alone.

These findings provided the first clinical validation that simultaneous inhibition of RAF dimers and downstream MEK could effectively suppress NRAS -driven MAPK signaling. Later data has shown higher response rate in cases of BRAF fusions [odds ratio (OR) 60%] compared to cases with BRAF point mutations class II or III (no responses) ( 39 ).

Nevertheless, belvarafenib exhibits relatively broad kinase inhibition beyond RAF family members, potentially contributing to dose-limiting toxicities and restricting therapeutic exposure ( 44 ). Naporafenib Naporafenib represents another second-generation type II pan-RAF inhibitor evaluated predominantly in combination with trametinib.

Clinical studies have demonstrated objective responses approaching 45–50% in NRAS -mutant melanoma, confirming that dual RAF/MEK inhibition consistently outperforms MEK inhibition alone ( 41 ). Although clinical efficacy appears broadly comparable to belvarafenib, biochemical profiling has revealed more specific inhibition than belvarafenib ( 44 ).

Whether these differences translate into clinically meaningful variations in efficacy or tolerability remains under investigation. Exarafenib Among currently available pan-RAF inhibitors, exarafenib represents one of the most pharmacologically refined molecules ( 44 ). Comprehensive kinome profiling has demonstrated remarkably high selectivity for RAF family kinases with substantially fewer off-target interactions than either belvarafenib or naporafenib.

This improved specificity is particularly relevant because inhibition of unrelated kinases may contribute to dose-limiting toxicities without enhancing antitumor activity ( 44 ). Preclinical studies have demonstrated potent inhibition across multiple BRAF mutation classes and broad activity in tumors driven by NRAS and other RAS alterations.

Importantly, exarafenib effectively suppresses signaling in CRAF -dependent cellular models, consistent with the biological dependence of NRAS -mutant melanoma on RAF dimer signaling ( 44 ). Early-phase clinical studies have confirmed a manageable safety profile, with predominantly grade 1–2 treatment-related adverse events.

The most common severe toxicities include reversible elevations of hepatic transaminases, rash, and acneiform dermatitis. Although objective responses were observed across several tumor types harboring MAPK pathway alterations, particularly Class II BRAF mutations, preliminary clinical experience also suggests durable disease control in selected patients with NRAS -mutant melanoma, supporting further clinical development ( 13 , 45 ).

Tovorafenib Unlike the previous compounds, tovorafenib is a pan-RAF inhibitor with excellent central nervous system penetration. It has been approved for pediatric low-grade gliomas harboring activating BRAF alterations and has generated considerable interest for tumors characterized by BRAF or CRAF fusions ( 42 ).

Preclinical studies have demonstrated potent activity of tovorafenib against BRAF fusion-driven tumor models, supporting the broader applicability of type II RAF inhibition beyond canonical BRAF V600 mutations. However, clinical evidence in fusion-positive melanoma remains limited, demonstrating activity in BRAF mutant previously untreated melanomas, but no activity in NRAS mutation ( 43 ).

Emerging challenges for pan-RAF inhibition Despite these encouraging advances, pan-RAF inhibitors do not completely eliminate adaptive MAPK reactivation. Recent mechanistic studies have identified alternative signaling complexes involving ARAF and KSR proteins that restore downstream ERK activation despite effective RAF inhibition ( 44 ).

Additional resistance mechanisms could include activation of RTKs, increased RAS signaling, ERK reactivation, and engagement of parallel pathways such as PI3K-AKT and FAK signaling. These observations indicate that pan-RAF inhibitors are unlikely to provide durable disease control as monotherapy.

Instead, their greatest clinical potential will probably emerge through rational combination strategies with other inhibitors as ERK inhibitors, immune checkpoint blockade, FAK inhibitors, or direct RAS-targeted therapies. Next-generation therapeutic strategies The limitations of conventional BRAF, MEK, and pan-RAF inhibition have stimulated the development of therapeutic strategies that extend beyond classical ATP-competitive kinase inhibition.

These approaches exploit distinct pharmacological mechanisms, including stabilization of inactive signaling complexes, direct RAS inhibition, targeted protein degradation, and prevention of paradoxical RAF activation ( Figure 3 ; Table 2 ). RAF-MEK molecular glues Among the most conceptually innovative therapeutic approaches are RAF-MEK molecular glues.

Unlike conventional kinase inhibitors, which compete with ATP binding, molecular glues exploit endogenous protein–protein interactions to stabilize inactive signaling complexes. NST-628 is the prototype of this new drug class. Rather than directly inhibiting RAF catalytic activity, it simultaneously engages RAF and MEK, locking both proteins into an inactive complex that prevents MEK phosphorylation while also inhibiting MEK catalytic activity.

Structural studies have demonstrated that this mechanism prevents productive assembly of active RAF dimers and effectively suppresses signaling downstream of all RAF isoforms ( 46 ). Importantly, NST-628 differs fundamentally from both selective BRAFi and pan-RAF inhibitors. Because its activity depends on stabilizing inactive RAF-MEK complexes rather than competing for kinase activity, pathway inhibition appears deeper and considerably more durable in preclinical models.

Moreover, by preventing BRAF - CRAF heterodimer formation, molecular glues directly target one of the principal mechanisms responsible for adaptive MAPK reactivation. Extensive preclinical evaluation has demonstrated broad activity across tumors harboring NRAS , KRAS , HRAS , and BRAF alterations ( 46 ).

Particularly relevant for melanoma, NST-628 has shown activity in experimental models resistant to both BRAF inhibition and immune checkpoint blockade, suggesting that stabilization of inactive signaling complexes may overcome resistance mechanisms not addressed by previous generations of MAPK inhibitors.

Early clinical data with NST-628 suggest a manageable safety profile, with predominantly grade 1–2 adverse events; the most common toxicities include rash, diarrhea, CK elevation, and retinopathy. Although clinical experience remains limited, RAF-MEK molecular glues represent one of the most promising approaches currently entering early-phase clinical development.

RAF-MEK clamps A concept closely related to molecular glues is represented by RAF-MEK clamp inhibitors, exemplified by avutometinib. Although both strategies stabilize inactive RAF-MEK complexes, important mechanistic differences distinguish these therapeutic classes. Unlike molecular glues, which actively promote formation of new protein interactions, avutometinib functions as an allosteric MEK inhibitor that stabilizes pre-existing RAF-MEK complexes in an inactive conformation.

This effectively prevents RAF-mediated phosphorylation of MEK and reduces the rapid adaptive ERK reactivation that frequently limits the efficacy of classical MEK inhibitors. This mechanism has important biological implications. Conventional MEK inhibitors suppress MEK catalytic activity but leave upstream RAF signaling largely intact, facilitating feedback-mediated pathway recovery.

By contrast, RAF-MEK clamps simultaneously interfere with upstream and downstream signaling, producing more sustained inhibition of ERK activation. The clinical relevance of this strategy has become particularly evident through combination approaches. One of the most promising involves simultaneous inhibition of FAK using defactinib ( 22 ).

Increasing evidence indicates that FAK signaling contributes to adaptive resistance following MAPK inhibition by promoting extracellular matrix remodeling, YAP activation, epithelial plasticity, and RTK signaling ( 47 ). Preclinical studies have demonstrated marked synergy between RAF-MEK clamp inhibition and FAK blockade, while encouraging clinical activity has already been reported in KRAS -mutant low-grade serous ovarian carcinoma ( 48 , 49 ) ( Figure 3 ).

In melanoma models with NRAS mutation or NF1 loss, the combination of VS-4718 and avutometinib significantly reduced melanoma cell growth ( 50 ). Although clinical experience in melanoma remains limited, these observations provide a strong rationale for evaluating similar combinations in NRAS -mutant disease.

Avutometinib-based therapy has shown a manageable safety profile, with the most relevant toxicities including creatine phosphokinase elevation, gastrointestinal and cutaneous adverse events, which generally can be managed with supportive care and dose modifications. ( 49 ) Direct RAS inhibition For more than three decades, RAS proteins were widely regarded as undruggable because of their exceptionally high affinity for GTP and the absence of suitable ligand-binding pockets.

This paradigm changed dramatically following the development of covalent KRAS G12C inhibitors, which transformed the treatment landscape of non-small cell lung cancer ( 16 , 17 , 51 , 52 ). Although KRAS G12C mutations are rare in melanoma, the conceptual impact of these discoveries extends far beyond a single mutation.

The demonstration that direct pharmacological inhibition of RAS is feasible has stimulated intense efforts to develop compounds capable of targeting multiple RAS isoforms, including NRAS . Among these emerging approaches, tri-complex inhibitors represent one of the most innovative strategies.

Tri-complex inhibitors: targeting activated RAS independent of mutation subtype Tri-complex inhibitors introduce a completely different therapeutic paradigm by targeting activated RAS rather than its downstream effectors. Instead of directly inhibiting kinase activity, these molecules bind GTP-loaded RAS and simultaneously recruit the intracellular chaperone cyclophilin A, generating a synthetic ternary complex that sterically prevents interaction between RAS and RAF ( 18 , 31 ).

Daraxonrasib is currently the leading representative of this drug class. Importantly, because its mechanism depends on the active conformation of RAS rather than a specific amino acid substitution, tri-complex inhibitors may theoretically inhibit multiple oncogenic RAS isoforms, including KRAS , NRAS , and HRAS .

Although current clinical development has primarily focused on KRAS -driven lung cancer ( 53 ) and pancreatic cancer ( 18 ), the biological rationale for evaluating these compounds in NRAS -mutant melanoma is compelling ( 20 , 31 ) and results from cases reports support its activity in melanoma ( 31 ).

Preclinical studies suggest potential synergy with immune checkpoint inhibition, likely through modulation of the tumor immune microenvironment and enhancement of T-cell activity ( 31 ). Resistant molecular mechanisms have been described consisting on the development of new mutations in RASY71 and RASY64 ( 54 ).

Whether these encouraging findings will translate into meaningful clinical benefit in melanoma remains to be established, but tri-complex inhibitors represent one of the most exciting areas of translational research in MAPK-targeted therapy. Targeted protein degradation An alternative strategy to overcome kinase-dependent resistance consists of eliminating the target protein altogether.

PROTACs recruit disease-associated proteins to endogenous E3 ubiquitin ligases, resulting in selective ubiquitination and subsequent proteasomal degradation. CFT1946 is a RAF degrader specifically designed for MAPK-driven tumors. Rather than competing with ATP, it induces degradation of mutant BRAF proteins, thereby eliminating signaling regardless of kinase conformation or dimerization status.

CFT1946 has been developed as an orally bioavailable, and brain-penetrant degrader that selectively targets BRAF V600-mutant proteins while sparing wild-type RAF family members. By promoting the degradation of the BRAF -V600X oncoprotein, CFT1946 effectively overcomes both RAF dimer-mediated and EGFR-mediated resistance mechanisms that compromise the activity of conventional BRAFi.

Preclinical studies had demonstrated robust antitumor activity in melanoma and colorectal cancer models harboring BRAF V600 mutations, including intracranial melanoma models and multiple patient-derived models of acquired or adaptive RAF dimer–driven resistance. Importantly, CFT1946 preserved wild-type MAPK signaling and mitigates the paradoxical pathway activation associated with approved BRAFi, resulting in a favorable therapeutic index.

Preliminary results from the ongoing phase I study of CFT1946 had demonstrated a favorable safety profile and encouraging signs of clinical activity in heavily pretreated patients with BRAF V600-mutant solid tumors, including melanoma, colorectal cancer, and NSCLC. Most patients had previously received BRAFi, reflecting a population with acquired resistance to current targeted therapies.

No dose-limiting toxicities or treatment-related grade 3 adverse events were observed, while pharmacodynamic analyses confirmed on-target activity through degradation of BRAF V600 protein and reductions in circulating BRAF V600E/K/R mutant allele fractions. Early evidence of antitumor activity included an unconfirmed partial response at the time of data cutoff, disease stabilization or better in 50% of efficacy-evaluable patients, and an additional unconfirmed partial response reported after the cutoff in a patient with BRAFi-refractory disease, who achieved a 64% reduction in target lesions ( 55 ).

Despite these preliminary findings, the sponsor subsequently decided not to pursue further clinical development of CFT1946, tempering its immediate therapeutic prospects while preserving proof of concept for BRAF-targeted protein degradation. Beyond CFT1946, several BRAF- and MEK-targeting PROTACs have demonstrated promising preclinical activity and highlight the potential of targeted protein degradation as a next-generation strategy for MAPK pathway inhibition in melanoma.

Early BRAF degraders, including Compound-2, P4B, and SJF-0628, established proof of concept that selective degradation of mutant BRAF can achieve more sustained suppression of MAPK signaling than conventional kinase inhibition while overcoming resistance mechanisms associated with RAF dimerization.

In particular, SJF-0628 and P4B showed potent activity in BRAF V600-mutant and BRAFi-resistant melanoma models, with minimal degradation of wild-type BRAF, suggesting an improved therapeutic window. More recently, PROTACs targeting MEK1/2 have also emerged as attractive candidates, as degradation of MEK may provide more durable pathway inhibition than catalytic inhibition alone and potentially delay or overcome adaptive MAPK reactivation.

Although these compounds remain at an early preclinical stage, they underscore the growing interest in targeted protein degradation as a complementary approach to conventional MAPK inhibitors and provide a strong rationale for the continued development of degraders targeting multiple nodes of the MAPK cascade ( 56 ).

Paradox breakers Paradoxical activation remains one of the defining limitations of first-generation BRAFi ( 30 ). Paradox breakers were specifically designed to preserve inhibition of mutant BRAF while minimizing activation of wild-type RAF dimers. Plixorafenib (PLX8394) is currently the only clinically advanced paradox-breaker RAF inhibitor.

Structural studies indicate that its distinct binding mode limits allosteric transactivation within RAF dimers while maintaining activity against mutant BRAF . In preclinical models, PLX8394 retained potent activity against BRAF V600-mutant tumors, did not induce ERK activation in BRAF wild-type cells, and overcame several resistance mechanisms associated with first-generation BRAFi, particularly those driven by RAF dimerization, providing the rationale for its subsequent clinical development. ( 57 ).

More recent preclinical studies have expanded the therapeutic scope of plixorafenib, demonstrating potent activity not only against BRAF V600 mutations but also across a broad range of non-V600 BRAF alterations, including class II and III mutations and BRAF fusions. Notably, plixorafenib showed greater potency than vemurafenib and, in some BRAF fusions, superior activity to the pan-RAF inhibitor tovorafenib, suggesting that its clinical utility may extend beyond BRAF V600-mutant tumors ( 58 ).

Preliminary results from the phase I/IIa trial demonstrated encouraging clinical activity and a favorable safety profile for plixorafenib in patients with advanced BRAF V600-altered solid tumors. Clinical benefit was observed in both MAPK inhibitor-naïve and previously treated patients, although responses were more frequent and durable in the treatment-naïve population.

The ORR was 37.5% in MAPK inhibitor-naïve patients compared with 16.7% in previously treated patients, with median durations of response of 32.3 and 12.9 months, respectively. Notably, median PFS exceeded two years in patients who had not previously received MAPK inhibitors. Based on its favorable benefit-risk profile, the recommended phase II dose was established as 900 mg once daily in combination with cobicistat.

These findings support the clinical development of plixorafenib as a next-generation “paradox-breaker” RAF inhibitor, particularly in patients with BRAF V600-mutant tumors who have not been previously exposed to MAPK-targeted therapy ( 59 ). Recent clinical and translational data have further expanded the therapeutic potential of plixorafenib.

Besides retaining activity in BRAF V600 tumors, plixorafenib demonstrates potent inhibition of class II BRAF mutations and BRAF fusions, broadening its spectrum beyond that of first-generation BRAFi. Clinical benefit appears to be greatest in patients without prior exposure to BRAFi, suggesting that earlier use may maximize efficacy.

Furthermore, longitudinal circulating tumor DNA (ctDNA) analyses revealed sustained suppression of mutant BRAF allele frequency without the emergence of acquired MAPK pathway alterations at progression, supporting the unique “paradox-breaker” mechanism of plixorafenib and indicating that resistance may instead arise through alternative pathways such as NF1, RAS, PI3K, or RTK signaling ( 60 ).

Although still undergoing clinical evaluation, paradox breakers may represent an attractive option for tumors characterized by atypical BRAF alterations, fusion proteins, or central nervous system involvement. Adaptive resistance to MAPK inhibition One of the most important lessons learned from two decades of MAPK-targeted drug development is that inhibition of a single oncogenic kinase rarely produces durable responses.

Regardless of whether tumors are treated with selective BRAFi, MEK inhibitors, or next-generation pan-RAF compounds, adaptive resistance almost invariably emerges through reactivation of MAPK signaling or activation of parallel survival pathways. Importantly, many of these resistance mechanisms do not result from secondary genetic alterations but instead reflect the remarkable signaling plasticity of melanoma cells.

Unlike other oncogene-addicted malignancies, melanoma possesses an exceptional capacity to dynamically rewire intracellular signaling in response to therapeutic pressure. This adaptive behavior explains why increasingly potent kinase inhibitors have often produced only incremental improvements in PFS, despite achieving profound initial suppression of ERK signaling.

Understanding these adaptive mechanisms has fundamentally shifted therapeutic development from empirical drug combinations toward biologically rational strategies targeting complementary signaling networks. MAPK pathway reactivation Reactivation of ERK signaling remains the principal mechanism of resistance across virtually all classes of MAPK inhibitors.

Although the molecular events responsible for pathway recovery vary according to the therapeutic agent and tumor genotype, the biological consequence is remarkably consistent: restoration of ERK activity despite continued drug exposure. Several mechanisms contribute to this process, including increased RTK signaling, enhanced RAS activation, RAF amplification, alternative RAF dimer formation, secondary mutations affecting MAPK components, and relief of negative feedback loops.

Importantly, many of these adaptive events occur within hours or days after treatment initiation, preceding the emergence of stable genomic resistance. Recent structural studies have further demonstrated that inhibition of one RAF isoform may favor assembly of alternative signaling complexes involving ARAF , CRAF , and scaffold proteins such as KSR1 and KSR2 .

These complexes restore MEK phosphorylation despite persistent inhibition of the original therapeutic target, illustrating the remarkable redundancy of MAPK signaling. Among these mechanisms, the recently described ARAF - KSR1 complex represents a particularly intriguing example ( 44 ).

Following prolonged RAF inhibition, melanoma cells may assemble alternative ARAF -containing signaling complexes capable of restoring downstream ERK activation independently of the inhibited RAF proteins. This adaptive rewiring provides a compelling explanation for the incomplete durability of even highly selective pan-RAF inhibitors such as exarafenib and highlights the need for therapeutic strategies capable of simultaneously targeting multiple signaling nodes.

These observations also explain why next-generation agents—including molecular glues and RAF-MEK clamps—attempt to prevent signaling complex formation rather than simply inhibit kinase activity. FAK signaling Increasing evidence indicates that FAK represents one of the principal adaptive survival pathways activated following MAPK inhibition.

Beyond its well-established role in cell adhesion and migration, FAK integrates extracellular matrix remodeling with intracellular signaling through PI3K, SRC, RHO GTPases, and YAP/TAZ transcriptional programs. MAPK inhibition frequently induces compensatory activation of FAK signaling, promoting cellular survival, invasion, epithelial plasticity, and resistance to apoptosis ( 22 ).

Particularly relevant in melanoma, FAK also modulates interactions between tumor cells and the surrounding stromal microenvironment, contributing to immune evasion and therapeutic resistance. Experimental studies have demonstrated that inhibition of FAK restores sensitivity to MAPK inhibition and enhances antitumor immune responses, providing a compelling rationale for combination strategies.

The clinical development of the RAF-MEK clamp avutometinib together with the FAK inhibitor defactinib represents the most advanced example of this concept. Although initially developed for KRAS -mutant low-grade serous ovarian carcinoma, this combination provides a strong biological framework that may be directly applicable to NRAS -mutant melanoma ( 47 , 49 ).

YAP/TAZ Another increasingly recognized mechanism of adaptive resistance involves activation of the Hippo pathway effector YAP. YAP functions as a transcriptional co-activator regulating cellular proliferation, stemness, metabolic adaptation, and resistance to apoptosis. Unlike genomic resistance mechanisms, YAP activation frequently reflects epigenetic adaptation induced by extracellular matrix remodeling, mechanical stress, and FAK activation.

Several studies have demonstrated that YAP activation mediates intrinsic resistance to BRAF and MEK inhibition while promoting a dedifferentiated melanoma phenotype characterized by increased invasiveness and reduced immunogenicity ( 23 ). Importantly, FAK and YAP appear to function as interconnected signaling modules.

FAK activation enhances nuclear localization of YAP, while YAP transcriptionally regulates multiple components of focal adhesion signaling, generating a positive feedback loop that reinforces therapeutic resistance ( 61 , 62 ). These observations further support simultaneous inhibition of MAPK and FAK/YAP signaling as a rational therapeutic strategy.

SOS1 Although NF1 -deficient tumors exhibit constitutive RAS activation, recent work has demonstrated that they remain partially dependent on guanine nucleotide exchange factors, particularly SOS1 , for sustained MAPK signaling ( 63 ). SOS1 catalyzes the exchange of GDP for GTP on RAS proteins, thereby maintaining active RAS signaling despite loss of NF1 -mediated GTP hydrolysis.

Pharmacological inhibition of SOS1 reduces RAS-GTP levels and has demonstrated strong synergy with MEK inhibition in preclinical NF1-mutant melanoma models ( 63 ). These findings challenge the traditional concept that NF1 -deficient tumors are completely independent of upstream signaling and suggest that combined inhibition of SOS1 together with next-generation MAPK inhibitors may provide a novel therapeutic opportunity for this clinically challenging subgroup.

STAT3, inflammatory signaling and immune adaptation Adaptive resistance is not restricted to tumor-intrinsic signaling pathways. Increasing evidence indicates that chronic MAPK inhibition profoundly remodels the tumor immune microenvironment. Activation of STAT3 signaling promotes secretion of immunosuppressive cytokines, recruitment of myeloid-derived suppressor cells, macrophage polarization, and T-cell dysfunction.

In parallel, MAPK inhibition may induce inflammatory transcriptional programs that paradoxically facilitate long-term immune escape ( 64 ). Future therapeutic strategies The rapid expansion of next-generation MAPK-targeted therapies has transformed the therapeutic landscape from one dominated by isolated kinase inhibitors into a multidimensional network of biologically rational therapeutic opportunities.

While many of these compounds remain in early clinical development, collectively they indicate that the long-standing absence of effective targeted therapies for NRAS -mutant melanoma may finally be approaching an inflection point. The therapeutic implications of the resistance mechanisms discussed in Section “Adaptive resistance to MAPK inhibition” point toward a biomarker-guided, combination-based approach to MAPK-targeted therapy.

Rather than pursuing uniform pathway suppression, future strategies will need to match specific therapeutic platforms and combinations to tumor genotype, signaling dependencies, resistance mechanisms, and microenvironmental context. Prospective biomarker development and rational treatment sequencing will therefore be critical to translating next-generation MAPK inhibitors into durable clinical benefit.

Another important source of optimism comes from developments outside melanoma. The successful clinical implementation of KRAS G12C inhibitors has fundamentally altered the perception that RAS proteins are undruggable. More recently, direct KRAS inhibition has become integrated into treatment algorithms for both non-small cell lung cancer and pancreatic ductal adenocarcinoma, demonstrating that selective targeting of oncogenic RAS is clinically feasible.

Although NRAS lacks an equivalent mutation-specific inhibitor, these advances have catalyzed the development of pan-RAS inhibitors, tri-complex inhibitors, and additional approaches targeting activated RAS independently of mutation subtype. Importantly, many biological principles learned in KRAS -driven tumors, including mechanisms of adaptive resistance, rational combination strategies, and biomarker development, are likely to accelerate therapeutic progress in NRAS -mutant melanoma.

Thus, melanoma may benefit not only from melanoma-specific research but also from the extraordinary advances occurring across the broader field of RAS biology. Despite remarkable progress, several important challenges remain before next-generation MAPK-targeted therapies can be incorporated into routine clinical practice.

First, direct comparative studies between the different classes of inhibitors are lacking, making it difficult to define optimal therapeutic sequencing. Second, predictive biomarkers capable of identifying patients most likely to benefit from specific therapeutic approaches remain poorly established.

Third, many of the most promising strategies involve combinations of targeted therapies, raising concerns regarding cumulative toxicity, treatment adherence, and economic sustainability. Finally, resistance mechanisms continue to evolve as increasingly sophisticated inhibitors enter clinical development, suggesting that durable disease control will ultimately require dynamic therapeutic adaptation rather than static treatment algorithms.

Conclusions The therapeutic landscape of MAPK-driven melanoma is undergoing transformations since the introduction of selective BRAFi more than a decade ago. While patients harboring BRAF V600 mutations have experienced remarkable improvements through combined BRAF and MEK inhibition, the absence of effective targeted therapies for NRAS -mutant melanoma has remained one of the major unmet needs in precision oncology.

Advances in structural biology and systems-level understanding of MAPK signaling have fundamentally reshaped therapeutic development. Rather than viewing RAF proteins as isolated kinases, they are now recognized as dynamic components of an intricate signaling network regulated by dimerization, scaffold proteins, feedback loops, and adaptive rewiring.

This evolving biological framework has directly inspired the development of a new generation of therapeutic agents, including type II pan-RAF inhibitors, RAF-MEK molecular glues, RAF-MEK clamps, paradox breakers, targeted protein degraders, and, more recently, direct RAS-targeted therapies.

Among these strategies, type II pan-RAF inhibitors currently represent the most clinically advanced approach for NRAS -mutant melanoma, providing the first convincing evidence that comprehensive inhibition of RAF dimers and CRAF-dependent signaling may overcome the limitations of conventional MAPK inhibition.

Equally important, entirely novel therapeutic concepts—including tri-complex RAS inhibitors and molecular glues—suggest that future drug development will increasingly focus on manipulating signaling complexes rather than inhibiting individual enzymes. Nevertheless, durable clinical benefit will almost certainly require combination strategies.

Adaptive resistance remains an inherent feature of MAPK-driven tumors and arises through dynamic activation of complementary signaling networks involving FAK, YAP, SOS1, RTKs, ERK reactivation, metabolic rewiring, and immune modulation. These insights have shifted the field away from sequential monotherapy toward biologically informed therapeutic combinations capable of suppressing both oncogenic signaling and adaptive escape mechanisms.

The remarkable clinical success of KRAS -targeted therapies in lung and pancreatic cancers has also transformed expectations for RAS-directed drug development. Although direct inhibition of NRAS remains more challenging, the rapid emergence of pan-RAS inhibitors, tri-complex compounds, and additional mutation-agnostic approaches provides renewed optimism that the historical distinction between “druggable” and “undruggable” oncogenes is progressively disappearing.

Lessons learned from KRAS -driven malignancies will almost certainly accelerate therapeutic innovation in melanoma over the coming years. Finally, the future of precision medicine in melanoma will likely depend less on identifying a single optimal inhibitor than on understanding how multiple therapeutic platforms can be integrated according to tumor biology, adaptive signaling networks, and host immune responses.

Genomic classification alone is unlikely to be sufficient. Instead, comprehensive molecular, functional, and microenvironmental biomarkers will be required to guide personalized therapeutic combinations. Acknowledgments Figures were generated using NoteBookLM.

Footnote Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine for the series “Advances in Treatment for Melanoma”. The article has undergone external peer review. Peer Review File: Available at https://atm.amegroups.com/article/view/10.21037/atm-2026-0157/prf Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-2026-0157/coif ). The series “Advances in Treatment for Melanoma” was commissioned by the editorial office without any funding or sponsorship.

M.G.C. served as the unpaid Guest Editor of the series. R.R. serves as an unpaid Honorary Editor-in-Chief of Annals of Translational Medicine from June 2026 to May 2028. Additionally, M.G.C. reports serving as an investigator in clinical trials sponsored by Pierre Fabre and Revolution Medicine; receiving support for attending meetings and travel from Pierre Fabre; and receiving payment for lectures from Pierre Fabre.

The authors have no other conflicts of interest to declare. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: https://creativecommons.org/licenses/by-nc-nd/4.0/ . References Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

N Engl J Med 2025;392:11-22. [ Crossref ] [ PubMed ] Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol 2022;40:4178-88. [ Crossref ] [ PubMed ] Robert C, Grob JJ, Stroyakovskiy D, et al.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 2019;381:626-36. [ Crossref ] [ PubMed ] Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Lancet Oncol 2016;17:1248-60. [ Crossref ] [ PubMed ] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. [ Crossref ] [ PubMed ] Cancer Genome Atlas Network.

Genomic Classification of Cutaneous Melanoma. Cell 2015;161:1681-96. [ Crossref ] [ PubMed ] Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Cell 2004;116:855-67. [ Crossref ] [ PubMed ] Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell 2017;170:17-33. [ Crossref ] [ PubMed ] Prior IA, Hood FE, Hartley JL.

The Frequency of Ras Mutations in Cancer. Cancer Res 2020;80:2969-74. [ Crossref ] [ PubMed ] Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol 2017;18:435-45. [ Crossref ] [ PubMed ] Janku F, Kim TM, Iyer G, et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer 2024;196:113458. [ Crossref ] [ PubMed ] Yen I, Shanahan F, Lee J, et al.

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature 2021;594:418-23. [ Crossref ] [ PubMed ] Gambardella V, McKean M, Kim R, et al. Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma.

JCO Oncol Adv 2026;3:e2500114. Roskoski R Jr. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.

Pharmacol Res 2021;172:105806. [ Crossref ] [ PubMed ] Akamatsu H, Sakata S, Azuma K, et al. A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET). J Thorac Oncol 2025;20:775-85. [ Crossref ] [ PubMed ] Mok TSK, Yao W, Duruisseaux M, et al.

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. J Clin Oncol 2024;42:LBA8509. Heist RS, Koyama T, Murciano-Goroff YR, et al.

Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. J Clin Oncol 2024;42:3007. Wolpin BM, Park W, Garrido-Laguna I, et al.

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med 2026;394:1790-802. [ Crossref ] [ PubMed ] Entrialgo-Cadierno R, Morali K, Feliu I, et al. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

Cancer Cell 2026;44:1218-1234.e7. [ Crossref ] [ PubMed ] Foth M, Kim W, O'Toole KT, et al. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma. bioRxiv 2025;;2025:2025.12.18.695203.. Riordan JD, Nathanson TA, Varzavand A, et al.

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition. Oncogene 2025;44:4520-32. [ Crossref ] [ PubMed ] Almazan J, Turapov T, Kircher DA, et al. Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases.

Cell Rep Med 2025;6:101943. [ Crossref ] [ PubMed ] Lin L, Sabnis AJ, Chan E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 2015;47:250-6. [ Crossref ] [ PubMed ] Riedl JM, Matsubara H, McNeil R, et al.

Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell 2026;44:471-97. [ Crossref ] [ PubMed ] Haling JR, Sudhamsu J, Yen I, et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.

Cancer Cell 2014;26:402-13. [ Crossref ] [ PubMed ] Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90. [ Crossref ] [ PubMed ] Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 2017;548:234-8. [ Crossref ] [ PubMed ] Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway.

Cancer Discov 2019;9:329-41. [ Crossref ] [ PubMed ] Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006;66:9483-91. [ Crossref ] [ PubMed ] Poulikakos PI, Zhang C, Bollag G, et al.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30. [ Crossref ] [ PubMed ] Anastacio Da Costa Carvalho L, Tovbis Shifrin N, Phadke MS, et al. RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.

Cancer Immunol Res 2026;14:90-106. [ Crossref ] [ PubMed ] Chatziioannou E, Lallas K, Sinnberg T, et al. Insights into RAS-driven melanoma and its therapeutic implications. Cancer Treat Rev 2026;143:103090. [ Crossref ] [ PubMed ] Posch C, Sanlorenzo M, Vujic I, et al.

Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells. J Invest Dermatol 2016;136:2041-8. [ Crossref ] [ PubMed ] Edlundh-Rose E, Egyházi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Melanoma Res 2006;16:471-8. [ Crossref ] [ PubMed ] Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011;164:776-84. [ Crossref ] [ PubMed ] Jakob JA, Bassett RL Jr, Ng CS, et al.

NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-23. [ Crossref ] [ PubMed ] Wei X, Zou Z, Zhang W, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

Eur J Cancer 2024;202:114008. [ Crossref ] [ PubMed ] Zhang F, Wang B, Wu M, et al. Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review. Front Immunol 2025;16:1509173. [ Crossref ] [ PubMed ] Kim TW, Lee J, Shin SJ, et al.

661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation. Ann Oncol 2023;34:S465-6. Shin SJ, Lee J, Kim TM, et al.

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion. J Clin Oncol 2021;39:3007. de Braud F, Dooms C, Heist RS, et al. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.

J Clin Oncol 2023;41:2651-60. [ Crossref ] [ PubMed ] Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 2024;30:207-17. [ Crossref ] [ PubMed ] Rasco DW, Medina T, Corrie P, et al.

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol 2023;92:15-28. [ Crossref ] [ PubMed ] Manabe T, Bergo HC, Li Q, et al. Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Nat Commun 2026;17:2484. [ Crossref ] [ PubMed ] Wang TS, Lee C, Severson P, et al. Abstract 4927: Exarafenib (KIN-2787) is a potent, selective pan-RAF inhibitor with activity in preclinical models of BRAF class II/III mutant and NRAS mutant melanoma. Cancer Res 2023;83:4927.

Ryan MB, Quade B, Schenk N, et al. The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers. Cancer Discov 2024;14:1190-205. [ Crossref ] [ PubMed ] Lubrano S, Cervantes-Villagrana RD, Faraji F, et al.

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell 2025;43:428-445.e6. [ Crossref ] [ PubMed ] Ichihara E, Westover D, Meador CB, et al. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Cancer Res 2017;77:2990-3000. [ Crossref ] [ PubMed ] Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol 2025;43:2782-92. [ Crossref ] [ PubMed ] Almazan J.

Abstract 2232: Investigating the combined inhibition of RAF, MEK, and FAK in melanoma molecular subtypes. Cancer Res 2026;86:2232. Barlesi F, Felip E, Popat S, et al.

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202). J Clin Oncol 2024;42:TPS8653. Gregorc V, Majem M, Lo Russo G, et al.

Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. Lancet Oncol 2026;27:432-41. [ Crossref ] [ PubMed ] Punekar SR, Hong DS, Luo J, et al. 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC).

J Thorac Oncol 2025;20:S10-1. Sang B, Ye LF, Fu Z, et al. Disrupted molecular glue complex drives RAS inhibitor resistance.

Cell 2026;189:2918-33. Vieito M, McKean M, Spira AI, et al. 612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors.

Ann Oncol 2024;35:S490-1. Gentile G, D'Aguanno S, Di Martile M, et al. PROTAC-based protein degradation: a window of opportunity for melanoma therapy.

J Biomed Sci 2026;33:23. Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation.

Nature 2015;526:583-6. Cohen L, Filippov-Levy N, Billauer H, et al. Abstract A095: The paradox-breaker BRAFi plixorafenib (FORE8394) efficiently inhibits non-V600 mutations and fusions.

Mol Cancer Ther 2023;22:A095. De La Fuente MI, Rodon Ahnert J, Yaeger R, et al. Safety and efficacy of the novel BRAFi FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.

J Clin Oncol 2023;41:3006. Yaeger R, Sherman EJ, Fuente MDL, et al. Abstract 3248: Circulating tumor DNA analysis of patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in phase 1/2a study.

Cancer Res 2025;85:3248. Dawson JC, Serrels A, Stupack DG, et al. Targeting FAK in anticancer combination therapies.

Nat Rev Cancer 2021;21:313-24. [ Crossref ] [ PubMed ] Lachowski D, Cortes E, Robinson B, et al. FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis. FASEB J 2018;32:1099-107. [ Crossref ] [ PubMed ] Sudhakar N, Yan L, Qiryaqos F, et al.

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Mol Cancer Ther 2024;23:1418-30. [ Crossref ] [ PubMed ] Godugu D, Chilamakuri R, Agarwal S. STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies.

Biochim Biophys Acta Rev Cancer 2025;1880:189461. [ Crossref ] [ PubMed ] Cite this article as: Gonzalez-Cao M, Manzano JL, Puértolas T, Gonzales J, Rosell R. Beyond BRAF V600: emerging MAPK-targeted therapeutic strategies. Ann Transl Med 2026 ; 14 ( 5 ): 72 . doi: 10.21037/atm-2026-0157